Galantamine reversal was linked to lower emergence delirium after pediatric ENT anesthesia

Emergence delirium remains one of the most disruptive recovery-room problems in pediatric anesthesia, especially after sevoflurane-based anesthesia in preschool-aged children undergoing ear, nose and throat procedures. In this retrospective observational study from Krasnoyarsk Interdistrict Children’s Hospital No. 4, galantamine was evaluated in two roles at once: routine reversal of neuromuscular blockade and rescue treatment for impaired emergence. The signal was striking in both settings. Among 207 children aged 2 to 17 years, no child who received prophylactic galantamine had a PAED score above 10, while 19 of 105 children without routine reversal did.

The physiologic rationale is not hard to follow. Emergence delirium has long been linked to central cholinergic deficiency, and galantamine crosses the blood-brain barrier while inhibiting acetylcholinesterase. In a setting where residual neuromuscular blockade can muddy the clinical picture, worsen interaction, and complicate extubation, a drug that restores neuromuscular function while increasing cholinergic tone creates a plausible dual pathway. The study was not designed to prove mechanism, but the bedside pattern fits the hypothesis.

Prophylactic reversal was associated with a clean separation in PAED outcomes

The cohort included children who underwent elective ENT surgery between October 2025 and January 2026, predominantly adenoidectomy, tonsillotomy, or tonsillectomy under sevoflurane anesthesia. The comparison was pragmatic rather than randomized: the groups reflected the practice of two anesthesiologists. In the prophylactic group, all 102 children received galantamine for routine reversal of neuromuscular blockade. In the non-prophylactic group of 105 children, routine reversal was not used, and galantamine was reserved for impaired emergence or suspected residual block.

Across the first postoperative assessment after extubation in the operating room, before rescue treatment for impaired emergence, the primary endpoint diverged sharply. PAED > 10 occurred in 0 of 102 children in the prophylactic group and 19 of 105 children in the non-prophylactic group, a difference that reached p < 0.0001. Median PAED scores were also lower with routine reversal: 7 [6-8] versus 8 [6-9], p = 0.0015. Even though the absolute median difference was modest, the absence of any score above the delirium threshold in the galantamine group is clinically meaningful in a fast-moving recovery environment where agitation, airway tolerance, and staff workload all collide.

A single point matters here. No child receiving routine galantamine crossed the study’s delirium threshold.

Rescue dosing restored interaction without sedatives

The therapeutic experience is just as interesting as the prophylactic one. Intravenous galantamine, in doses ranging from 2.5 mg to 10 mg, was administered in 17 episodes of delirium characterized by motor agitation and impaired interaction. Resolution was documented in all 17 cases. The return was not described as mere quieting or pharmacologic suppression. Reduced agitation was accompanied by restoration of meaningful interaction, which suggests a shift toward organized emergence rather than simple sedation.

No sedatives were used to treat delirium in these episodes. In a pediatric post-anesthesia setting, that detail matters because sedatives can blur neurologic assessment and delay discharge readiness. The observed response raises a practical question about whether enhancing cholinergic transmission may help children traverse the transition from anesthetized state to coherent wakefulness more smoothly than sedation-based rescue strategies do. The authors even frame this as a hypothesis that galantamine could act as an agent promoting emergence from anesthesia, an idea that is biologically plausible given its central cholinergic activity and its existing use in neuromuscular block reversal.

Safety signals were limited, but the study was not built to settle them

The safety picture was reassuring within the narrow scope reported. No serious adverse events were documented. Emetic events in the first postoperative hour occurred in 17.6% of children with ondansetron prophylaxis and 21.9% with dexamethasone prophylaxis, with no statistically significant difference between those antiemetic strategies (p = 0.49). The abstract does not provide enough detail to attribute those events to galantamine or to separate them from the background emetic risk that can follow ENT surgery and sevoflurane anesthesia. Still, the absence of serious complications is notable for a drug being used both routinely and as rescue treatment in children.

The evidence remains observational, and the comparison is vulnerable to confounding because it was shaped by clinician practice rather than allocation by randomization. The groups also came from two anesthesiologists, which may capture different thresholds for diagnosing delirium, different extubation habits, or different approaches to recovery-room management. Even with those limitations, the investigators tried to strengthen internal consistency by checking PAED scores against clinical descriptions and correcting discrepancies when they found them. Ethical approval was obtained from the hospital ethics committee, which waived separate parental consent for anonymized retrospective data.

Why this preprint matters for pediatric anesthesia practice

Children undergoing ENT surgery already sit at a high-risk intersection for emergence delirium: young age, sevoflurane exposure, and the sensory disruption of airway surgery all stack risk in the same direction. A reversal agent that appears to improve both neuromuscular recovery and emergence behavior could be especially attractive in this setting, because the clinician is not choosing between airway recovery and behavioral recovery; the two are tightly linked. Residual blockade can make a child look inattentive, weak, or distressed, while central cholinergic deficiency may amplify agitation and disorientation. Galantamine targets both dimensions in a single intervention.

Still, this is a preprint and should not be treated as practice-changing proof. The findings need prospective confirmation, ideally with randomized allocation, predefined delirium assessment, and clearer adverse-event capture. The current dataset supports further study of prophylactic and therapeutic galantamine use, but it does not resolve whether the observed benefit is driven by better reversal of paralysis, a central cholinergic effect, or both. It also leaves open whether the same pattern would hold outside one hospital, one surgical mix, and one anesthesia workflow.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by medRxiv (Clinical Preprints).